Dong-A ST Co (170900) Fair Value & Analysis
Healthcare · KR · Market cap 361B KRW
Fair value as of: Jul 7, 2026
From 6 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 299,904 KRW to 10,611 KRW (−96.5%) since Jun 24, 2026. Share price −8.7% over the past month.
Price vs Fair Value (12 months)
12‑month range 32,000 KRW – 54,197 KRW · fair‑value band 10,611 KRW – 22,752 KRW · the 35,250 KRW price screens above the 10,611 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dong-A ST Co (170900) currently trades at 35,250 KRW, while our model-based Fair Value estimate is 10,611 KRW — implying the stock looks roughly 69.9% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Dong-A ST Co generated revenue of 830B KRW at a net margin of -1.4%. Revenue grew 11.8% year over year. It earns a return on equity of -2.5%. Net debt stands at 366B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 10,611 KRW (bear case) to 22,752 KRW (bull case); at 35,250 KRW, the current price sits above that range. The share trades about 36% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -70%, 170900 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome; Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Dong-A ST Co reported revenue of 809B KRW in FY2025 versus 593B KRW in FY2021, a compound +8.1%/yr. Reported net income was −28.6B KRW in FY2025.
Is 170900 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dong-A ST Co (170900) undervalued?
What is the fair value of 170900?
What is the quality score of 170900?
What is the revenue of Dong-A ST Co (170900)?
What is the net profit margin of 170900?
Does Dong-A ST Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.